Sarepta Therapeutics Q3 2026 net loss narrows 44% to $28.46 million

Bitget2026/11/05 21:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sarepta Therapeutics’ third-quarter 2026 net loss narrowed 44% year over year to $28.5 million.
Total revenues fell 5% to $381.4 million, primarily due to lower ELEVIDYS sales volumes following its restriction to ambulatory patients.
Research and development expenses dropped 62% to $82.5 million, primarily reflecting a prior-year $100 million Arrowhead milestone payment.
DM1 and FSHD multiple ascending dose data are expected in the fourth quarter of 2026, with Phase 3 preparations underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611051605BIZWIRE_USPR_____20261105_BW687672) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sarepta Therapeutics Q3 2026 net loss narrows 44% to $28.46 million

You may also like

Crypto prices